CORT · XBRL financial data

Corcept Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CORT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	353,874	365,978	401,858	482,375	675,040	761,407
Cost of goods and services sold	5,582	5,281	5,385	6,481	10,882	12,977
Research and development	114,764	113,864	130,991	184,353	246,887	254,908
Selling, general and administrative	105,326	122,356	152,848	184,259	280,320	448,725
Operating income (loss)	128,202	124,477	112,634	107,282	136,951	44,797
Income tax expense (benefit)	25,591	12,494	14,773	18,417	20,284	(33,189)
Net income (loss)	106,011	112,512	101,418	106,140	141,209	99,652
Earnings per share, basic USD per share	0.92	0.97	0.95	1.02	1.35	0.95
Earnings per share, diluted USD per share	0.85	0.89	0.87	0.94	1.23	0.82
Weighted average shares, basic thousands of shares	115,412	115,653	106,787	103,560	103,232	103,862
Weighted average shares, diluted thousands of shares	124,194	125,963	115,966	111,742	113,480	119,987

Fiscal years (CORT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	76,190	77,617	66,329	135,551	127,665	120,495
Marketable securities	364,506	145,918	365,343	232,670	255,669	251,657
Marketable securities, non-current	36,196	112,277	4,947	57,176	219,831	160,270
Accounts receivable	26,198	27,625	31,057	41,123	53,976	59,786
Inventory	4,910	4,988	6,100	7,730	12,412	12,868
Prepaid and other current assets	6,697	10,315	16,424	27,562	21,880	40,658
Total current assets	478,501	266,463	499,253	458,636	471,602	485,464
Property and equipment, net	1,675	1,002	633	195	2,689	1,890
Right-of-use asset	2,509	514	1,143	120	5,324	4,583
Total assets	571,731	423,756	583,430	621,517	840,553	836,651
Accounts payable	10,554	6,908	11,976	17,396	15,376	40,444
Accrued liabilities	21,186	27,665	30,799	51,628	90,700	90,603
Total current liabilities	47,494	47,541	72,491	104,505	140,773	166,085
Lease liability, non-current	501	0	—	0	6,107	5,023
Total liabilities	48,393	47,950	81,588	114,812	160,964	188,846
Retained earnings	82,456	194,968	296,386	402,526	543,735	643,387
Total stockholders' equity	523,338	375,806	501,842	506,705	679,589	647,805
Total liabilities and equity	571,731	423,756	583,430	621,517	840,553	836,651
Common shares outstanding (cover page) thousands of shares	117,312	105,962	107,899	103,517	105,503	106,374

Fiscal years (CORT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	106,011	112,512	101,418	106,140	141,209	99,652
Stock-based compensation	33,539	42,931	42,442	48,940	61,354	84,500
Depreciation and amortization	525	1,072	782	577	795	1,149
Net cash from operating activities	151,970	167,892	120,323	127,039	198,067	141,996
Purchases of property and equipment	1,238	469	413	139	2,172	211
Net cash from investing activities	(119,263)	136,126	(114,327)	90,906	(177,604)	69,758
Proceeds from issuing equity	23,226	16,229	4,381	5,811	—	—
Share repurchases	9,945	—	0	0	15,664	172,915
Net cash from financing activities	12,214	(302,591)	(17,284)	(148,723)	(28,349)	(220,366)
Net change in cash	44,921	1,427	(11,288)	69,222	(7,886)	(7,170)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Corcept Therapeutics	98,720	340,472	142,891*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	726,960	209,314	43,099*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036,400	1,243,000	506,100*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Madrigal Pharmaceuticals	514,642	431,268	120,556*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736,007	1,024,646	188,214*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815,435	not reported	(387,319)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Ionis Pharmaceuticals	350,065	267,949	565,531*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631,314	480,132	93,477*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163,138	480,999	240,891*	113.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.